Bayer Aktiengesellschaft (BAYRY) shares ended the last trading session 6% higher at $14.4. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 4.9% gain over the past four weeks.The stock rallied after Bayer’s subsidiary Monsanto proposed a nationwide U.S. class-action settlement. The plan aims to resolve current and future Roundup lawsuits alleging that the product caused Non-Hodgkin lymphoma (NHL) through a long-term ...

Core Viewpoint - The article discusses the momentum investing strategy, emphasizing the importance of following a stock's recent price trends to make profitable trades, particularly focusing on Bayer Aktiengesellschaft (BAYRY) as a potential momentum pick [1][3][12]. Company Overview - Bayer Aktiengesellschaft currently holds a Momentum Style Score of B and a Zacks Rank of 2 (Buy), indicating a favorable outlook for the stock [3][4][12]. Performance Metrics - Over the past week, BAYRY shares increased by 1.98%, while the Zacks Large Cap Pharmaceuticals industry rose by 2.03%. In a longer timeframe, BAYRY's monthly price change is 19.32%, outperforming the industry's 7.35% [6]. - In the last three months, BAYRY shares have surged by 71.91%, and over the past year, they have risen by 152.2%. In comparison, the S&P 500 has only moved 3.73% and 16.78%, respectively [7]. Trading Volume - The average 20-day trading volume for BAYRY is 1,392,979 shares, which serves as a bullish indicator when combined with rising stock prices [8]. Earnings Outlook - In terms of earnings estimates, there has been one upward revision in the past two months, increasing the consensus estimate from $1.41 to $1.42 for the full year. For the next fiscal year, one estimate has also moved upwards with no downward revisions [10]. Conclusion - Considering the positive performance metrics and earnings outlook, BAYRY is positioned as a strong buy candidate for investors looking for momentum stocks [12].

Core Insights - AbbVie reported quarterly earnings of $2.71 per share, exceeding the Zacks Consensus Estimate of $2.66 per share, and showing an increase from $2.16 per share a year ago, resulting in an earnings surprise of +2.02% [1] - The company achieved revenues of $16.62 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.58% and increasing from $15.1 billion year-over-year [2] Earnings Performance - AbbVie has consistently surpassed consensus EPS estimates over the last four quarters, with the latest earnings surprise being +5.08% compared to the previous quarter's expectation of $1.77 per share [1][2] - The current consensus EPS estimate for the upcoming quarter is $3.12, with projected revenues of $15.2 billion, and for the current fiscal year, the estimate is $14.32 on revenues of $67.28 billion [7] Stock Performance and Outlook - AbbVie shares have underperformed the market, losing about 1.2% since the beginning of the year, while the S&P 500 has gained 1.1% [3] - The stock currently holds a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Large Cap Pharmaceuticals industry, to which AbbVie belongs, is currently ranked in the bottom 22% of over 250 Zacks industries, suggesting potential challenges ahead [8]

Core Insights - Eli Lilly (LLY) reported quarterly earnings of $7.54 per share, exceeding the Zacks Consensus Estimate of $6.99 per share, and up from $5.32 per share a year ago, representing an earnings surprise of +7.88% [1] - The company posted revenues of $19.29 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 7.95%, compared to $13.53 billion in the same quarter last year [2] - Lilly has surpassed consensus EPS estimates three times over the last four quarters and topped revenue estimates four times during the same period [2] Future Outlook - The sustainability of the stock's price movement will depend on management's commentary during the earnings call and the earnings outlook for the coming quarters [3][4] - The current consensus EPS estimate for the next quarter is $6.96 on revenues of $16.75 billion, and for the current fiscal year, it is $33.24 on revenues of $77.52 billion [7] - The estimate revisions trend for Lilly was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Large Cap Pharmaceuticals industry, to which Lilly belongs, is currently in the bottom 22% of over 250 Zacks industries, suggesting potential challenges ahead [8] - The performance of Lilly's stock may also be influenced by the overall outlook for the industry, as research indicates that the top 50% of Zacks-ranked industries outperform the bottom 50% by more than 2 to 1 [8]

分组1 - Pfizer reported quarterly earnings of $0.66 per share, exceeding the Zacks Consensus Estimate of $0.57 per share, and showing an increase from $0.63 per share a year ago, resulting in an earnings surprise of +16.81% [1] - The company achieved revenues of $17.56 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 4.26%, although this represents a decline from year-ago revenues of $17.76 billion [2] - Pfizer has surpassed consensus EPS estimates in all four of the last quarters and has topped consensus revenue estimates three times during the same period [2] 分组2 - The stock has gained approximately 7.1% since the beginning of the year, outperforming the S&P 500, which has gained 1.9% [3] - The future performance of Pfizer's stock will largely depend on management's commentary during the earnings call and the outlook for earnings estimates [3][4] - The current consensus EPS estimate for the upcoming quarter is $0.75 on revenues of $13.9 billion, and for the current fiscal year, it is $2.97 on revenues of $60.81 billion [7] 分组3 - The Large Cap Pharmaceuticals industry, to which Pfizer belongs, is currently ranked in the bottom 23% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - The Zacks Rank for Pfizer is currently 5 (Strong Sell), suggesting that the stock is expected to underperform the market in the near future [6]

Core Insights - Merck reported quarterly earnings of $2.04 per share, exceeding the Zacks Consensus Estimate of $2.03 per share, and showing an increase from $1.72 per share a year ago, resulting in an earnings surprise of +0.62% [1] - The company achieved revenues of $16.4 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.33% and up from $15.62 billion year-over-year [2] - Merck's stock has increased by approximately 7.7% since the beginning of the year, outperforming the S&P 500's gain of 1.9% [3] Earnings Outlook - The future performance of Merck's stock will largely depend on management's commentary during the earnings call and the company's earnings outlook [4] - The current consensus EPS estimate for the upcoming quarter is $0.32 on revenues of $16.13 billion, and for the current fiscal year, it is $6.20 on revenues of $67.36 billion [7] Estimate Revisions - Prior to the earnings release, the estimate revisions trend for Merck was unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5] Industry Context - The Large Cap Pharmaceuticals industry, to which Merck belongs, is currently ranked in the bottom 23% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Another company in the same industry, Eli Lilly, is expected to report quarterly earnings of $6.99 per share, reflecting a year-over-year increase of +31.4%, with revenues projected at $17.87 billion, up 32.1% from the previous year [9][10]

Core Viewpoint - Eli Lilly (LLY) is positioned to potentially continue its earnings-beat streak in the upcoming report, having a history of exceeding earnings estimates, particularly in the last two quarters with an average surprise of 14.54% [1] Earnings Performance - For the last reported quarter, Eli Lilly achieved earnings of $7.02 per share, surpassing the Zacks Consensus Estimate of $6.02 per share, resulting in a surprise of 16.61% [2] - In the previous quarter, the company was expected to report earnings of $5.61 per share but delivered $6.31 per share, yielding a surprise of 12.48% [2] Earnings Estimates and Predictions - There has been a favorable change in earnings estimates for Eli Lilly, with a positive Zacks Earnings ESP (Expected Surprise Prediction), indicating a strong likelihood of an earnings beat [5] - Stocks with a positive Earnings ESP and a Zacks Rank of 3 (Hold) or better have historically produced a positive surprise nearly 70% of the time, suggesting a high probability of exceeding consensus estimates [6] Earnings ESP Metric - The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate, with the Most Accurate Estimate reflecting the latest analyst revisions, which may be more accurate [7] - Eli Lilly currently has an Earnings ESP of +0.05%, indicating recent bullish sentiment among analysts regarding the company's earnings prospects [8] Upcoming Earnings Report - The next earnings report for Eli Lilly is expected to be released on February 4, 2026, and the combination of a positive Earnings ESP and a Zacks Rank of 3 suggests a potential for another earnings beat [8]

Core Viewpoint - AbbVie (ABBV) is anticipated to report a year-over-year increase in earnings and revenues for the quarter ended December 2025, with earnings expected to be $3.02 per share, reflecting a +39.8% change, and revenues projected at $16.38 billion, up 8.5% from the previous year [1][3]. Earnings Expectations - The upcoming earnings report is scheduled for February 4, and the stock may rise if the reported figures exceed expectations, while a miss could lead to a decline [2]. - The consensus EPS estimate has been revised 0.32% higher in the last 30 days, indicating a slight positive adjustment from analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that AbbVie has a negative Earnings ESP of -12.44%, suggesting analysts have become bearish on the company's earnings prospects [12]. - Despite the negative Earnings ESP, AbbVie holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - AbbVie has a history of beating consensus EPS estimates, having done so in the last four quarters, with a recent surprise of +5.08% when it reported earnings of $1.86 per share against an expectation of $1.77 [13][14]. Industry Context - In the broader pharmaceutical industry, Merck (MRK) is also expected to report earnings of $2.04 per share for the same quarter, reflecting a year-over-year change of +18.6%, with revenues projected at $16.19 billion, up 3.6% [18]. - Merck's consensus EPS estimate has been revised down by 85.2% over the last 30 days, and it currently has an Earnings ESP of +0.33% but holds a Zacks Rank of 4, complicating predictions for an earnings beat [19][20].

Core Viewpoint - Momentum investing focuses on following a stock's recent price trends, aiming to buy high and sell higher, with the expectation that established trends will continue [1] Group 1: Company Overview - Bayer Aktiengesellschaft (BAYRY) currently holds a Momentum Style Score of B, indicating potential as a solid momentum pick [2][3] - The company has a Zacks Rank of 2 (Buy), which is associated with strong historical performance [3] Group 2: Price Performance - BAYRY shares have increased by 14.7% over the past week, significantly outperforming the Zacks Large Cap Pharmaceuticals industry, which rose by only 0.67% [5] - Over the past month, BAYRY's price change is 20.42%, compared to the industry's 3.44% [5] - In the last quarter, BAYRY shares have surged by 59.9%, and over the past year, they have gained 130.96%, while the S&P 500 has only moved 2.42% and 14.97%, respectively [6] Group 3: Trading Volume - The average 20-day trading volume for BAYRY is 521,464 shares, which serves as a bullish indicator when combined with rising stock prices [7] Group 4: Earnings Outlook - In the past two months, one earnings estimate for BAYRY has increased, raising the consensus estimate from $1.33 to $1.42 [9] - For the next fiscal year, one estimate has also moved upwards, with no downward revisions during the same period [9] Group 5: Conclusion - Considering all factors, BAYRY is positioned as a 2 (Buy) stock with a Momentum Score of B, making it a noteworthy option for near-term investment [11]

分组1 - Johnson & Johnson reported quarterly earnings of $2.46 per share, exceeding the Zacks Consensus Estimate of $2.43 per share, and showing an increase from $2.04 per share a year ago, representing an earnings surprise of +1.05% [1] - The company achieved revenues of $24.56 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 1.84%, and up from $22.52 billion year-over-year [2] - Johnson & Johnson has consistently outperformed consensus EPS and revenue estimates over the last four quarters [2] 分组2 - The stock has increased approximately 5.4% since the beginning of the year, while the S&P 500 has declined by 0.7% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the next quarter is $2.75 on revenues of $23.05 billion, and for the current fiscal year, it is $11.46 on revenues of $98.46 billion [7] 分组3 - The Zacks Industry Rank indicates that the Large Cap Pharmaceuticals sector is in the top 41% of over 250 Zacks industries, suggesting a favorable outlook for stocks in this category [8] - Eli Lilly, another company in the same industry, is expected to report quarterly earnings of $7.50 per share, reflecting a year-over-year increase of +41%, with revenues projected at $18.21 billion, up 34.6% from the previous year [9]